IBA Selected to Install a Proton Therapy Center in Knoxville, Tennessee, USA

IBA reinforces its leadership in particle therapy by signing a term sheet for the installation of a new clinical proton therapy system in the USA

SAN DIEGO--(BUSINESS WIRE)-- IBA (Ion Beam Applications S.A.) announced today that ProVision Trust and The Proton Therapy Center, LLC (TPTC) have selected IBA for the installation of a Proton Therapy facility in Knoxville, Tennessee, USA.

The Proton Therapy Center, LLC (TPTC) at East Tennessee Healthcare Center (ETHC) in Knoxville, Tenn. ...

The Proton Therapy Center, LLC (TPTC) at East Tennessee Healthcare Center (ETHC) in Knoxville, Tenn., upon completion, will include two isocentric gantry treatment rooms, a fixed beam treatment room and a research room. (Photo: Business Wire)

This project, subject to financing, includes the supply and installation of a proton therapy facility consisting of two isocentric gantry treatment rooms, a fixed beam treatment room and a research room. In addition, it has been agreed that IBA will provide to the center operation and maintenance services for a period of 10 years. The contract represents total revenues of 70 to 80 million (USD) for IBA over the term of the agreement.

TPTC will be located at the East Tennessee Healthcare Center (ETHC). ETHC provides comprehensive, innovative care to patients in the diagnosis and treatment of cancer and other diseases. TPTC’s primary clinical partners will be the University of Tennessee Medical Center, the East Tennessee Children’s Hospital, Tennessee Cancer Specialists and the Knoxville Comprehensive Breast Center.

“We are proud to collaborate with ProVision in making proton therapy accessible to more cancer patients in the United States. We are honored to take part in this important project. In an effort to develop proton therapy even further, the installation of this new center will be accompanied by joint efforts in R&D and the operation of a training center,” said Pierre Mottet, Chief Executive Officer of IBA.

Terry D. Douglass, Ph.D., President of ProVision and TPTC, added “We have an opportunity here to develop a world-class comprehensive clinical and research cancer center with proton therapy as the primary treatment modality. Thanks to IBA, we will be able to offer this state of the art therapy to our region and even to the country as early as 2013. We are also excited about the agreement to partner with IBA in joint R&D, the training center, and other opportunities of mutual interest.”

IBA is committed to making Proton Therapy, the most accurate cancer treatment, available worldwide. To date, IBA has been selected to install 20 proton therapy centers of which 16 are firm orders which represent more than half of the clinical-based Proton Therapy facilities in the world.

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and, even better, spare healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving outcome and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.

ABOUT IBA
IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.
Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Website: www.iba-worldwide.com

ABOUT PROVISION
ProVision Trust is a member of the ProVision Group of organizations, which is developing the Center. ProVision is committed to improving patient care and outcomes with an emphasis placed on predictive, preventative, and personalized healthcare and advanced diagnostic and therapy management solutions.
Website: www.pvhealthcare.com

ABOUT ETHC
The East Tennessee Healthcare Center, LLC (ETHC), the location of TPTC, is a comprehensive healthcare Campus focusing on comprehensive and innovative patient care, research and education. ETHC is the largest provider of outpatient cancer-care services in East Tennessee and provides services for more than 50,000 cancer patient visits per year to its campus.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6494136&lang=en



CONTACT:

IBA
Thomas Ralet, +32 10 47 58 90
VP Corporate Communication
Email: [email protected]
or
ProVision and ETHC
Michael Bozeman, +1 865 712 3303
Director of Marketing
Email: [email protected]

KEYWORDS:   United States  North America  California  Tennessee

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Oncology

MEDIA:

Logo
 Logo
Photo
 Photo
The Proton Therapy Center, LLC (TPTC) at East Tennessee Healthcare Center (ETHC) in Knoxville, Tenn., upon completion, will include two isocentric gantry treatment rooms, a fixed beam treatment room and a research room. (Photo: Business Wire)

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.